Table 1. . Baseline demographics of study cohort: Commercial and Medicare patients grouped by experience of MG exacerbation.
| Commercial population (n = 5340) | Medicare population (n = 3423) | ||||
|---|---|---|---|---|---|
| Never exacerbation/crisis patients (n = 3634) | Patients with ≥1 exacerbation (n = 1706) | Never exacerbation/crisis patients (n = 2154) | Patients with ≥1 exacerbation (n = 1269) | ||
| Age, years | Mean (SD) | 50.09 (10.89) | 49.09 (11.55) | 74.89 (7.08) | 75.89 (7.43) |
| Median (IQR) | 53 (44–59) | 52 (42–59) | 75 (69–80) | 76 (70–81) | |
| Sex, n (%) | Female | 2096 (57.7) | 1014 (59.4) | 886 (41.1) | 534 (42.1) |
| Region, n (%) | Northeast | 729 (20.1) | 328 (19.2) | 516 (24.0) | 298 (23.5) |
| North Central | 758 (20.9) | 389 (22.8) | 643 (29.9) | 443 (34.9) | |
| South | 1516 (41.7) | 723 (42.4) | 677 (31.4) | 333 (26.2) | |
| West | 588 (16.2) | 247 (14.5) | 308 (14.3) | 190 (15.0) | |
| Unknown | 43 (1.2) | 19 (1.1) | 10 (0.5) | 5 (0.4) | |
| Comorbidities, n (%) | Anxiety disorders | 348 (9.6) | 228 (13.4) | 107 (5.0) | 102 (8.0) |
| Depression | 375 (10.3) | 217 (12.7) | 118 (5.5) | 119 (9.4) | |
| Diabetes (types I and II) | 548 (15.1) | 357 (20.9) | 633 (29.4) | 419 (33.0) | |
| Infection | 1344 (37.0) | 774 (45.4) | 943 (43.8) | 606 (47.8) | |
| Obesity | 218 (6.0) | 176 (10.3) | 87 (4.0) | 72 (5.7) | |
IQR: Interquartile range; MG: Myasthenia gravis; SD: Standard deviation.